Skip to main content
impaact logo Return to homepage
  • Contact
    • Directory
  • About
    • Mission
    • Network Structure
      • Leadership
    • Areas of Research
      • HIV Complications and Co-Morbidities
      • HIV Cure
      • HIV Treatment
      • Tuberculosis
    • Funding Acknowledgements
    • Network Sites
    • Staff Spotlight
  • Studies
    • Research and Study Opportunities
    • Submit a Research Proposal
    • IMPAACT Study Snapshots
  • Community Engagement
    • ICAB Leadership Group
    • IMPAACT Community Advisory Board (ICAB)
    • Operations Center Staff
    • Resources
      • Acronyms
    • Site Community Advisory Boards
  • News & Events
    • Conferences & Other Meetings
    • IMPAACT Annual Meeting
    • Newsletters
    • Past Conference Presentations
  • Resources
    • COVID-19 Resources
    • HIV/AIDS Network Coordination (HANC)
    • Lab Center
      • Laboratory Committees
      • Laboratory Guidance Documents
      • Laboratory Resources for Quality Management
      • Specimen Repository
    • Manual of Procedures
    • Network Logos & Templates
    • Regulatory Resources
    • Training Opportunities
  • Publications
    • Abstracts
    • Manuscripts
  • Enter a search term.
Back to Directory

Anneke C. Hesseling

Email

Phone

Institution

Stellenbosch University

Role

Senior Researcher

Address

Stellenbosch University
Department of Paediatrics and Child Health
Desmond Tutu TB Centre
Faculty of Health Sciences
PO Box 19063
Cape Town, Tygerberg 7505
South Africa
Request an Update

Affiliated Studies

P1026S: PK in Pregnancy

DAIDS Number

10040

Research Area

Treatment

Study Status

Closed to Follow Up

Locality

US & Non-US

IMPAACT 2020: SMaRT Kids

DAIDS Number

38505

Research Area

Tuberculosis

Study Status

In Development

Locality

Non-US

IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

DAIDS Number

38609

Research Area

Treatment

Study Status

Pending

Locality

US & Non-US

IMPAACT 2003B: Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx MDR-TB)

DAIDS Number

12041

Research Area

Tuberculosis

Study Status

Enrolling

Locality

Non-US

IMPAACT 2024 : Phase I/II Dose Finding and Safety Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Infants, Children and Adolescents

DAIDS Number

38747

Research Area

Tuberculosis

Study Status

In Development

Locality

US & Non-US
Show All
IMPAACT logo Return to homepage

Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.

Stay connected with the IMPAACT Network

Follow IMPAACT

Sign up for our newsletter

Sitemap

© 2020 IMPAACT Network